- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07726212
A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002
A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics, and Preliminary Efficacy of MC002 in Participants With Locally Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to learn if ADC drug MC002 works to treat locally advanced/metastatic solid tumors in adults. It will also learn about the safety of MC002. The main questions it aims to answer are:
Does participants tolerate the drug MC002 ? What medical problems do participants have when treating with MC002? Does participants benefit from the MC002
.
Participants will:
Intravenous infusion MC002 every 3 weeks in clinical Visit the clinic once every 3 weeks for checkups and tests Keep a diary of their symptoms
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Medical Director
- Telefonnummer: +86 13306139991
- E-post: ke.chen@mlkbiotech.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- 18 years of age and over, male or female, able to understand and willing to sign the Informed Consent Form (ICF).
- Life expectancy of 3 month or greater
- participants with histologically or cytologically confirmed recurrent or metastatic unresectable advanced solid tumors who experience disease progression after receiving systemic standard therapy, or have no standard therapy.
- At least one measurable lesion as assessed by RECIST 1.1
- Adequate organ functions.
- ECOG Performance Status (PS) of 0-1
Exclusion Criteria:
- Pregnant or nursing females.Participants who have received chemotherapy, investigational therapy, immunotherapy, or any other antitumor active drugs within 4 weeks or 5 half-lives (whichever is shorter) before the first dose.
- Known hypersensitivity to either the drug substances or inactive ingredient
- Participants who have undergone a bone marrow transplantation, solid organ transplantation, stem cell transplant.
- Participants with QTc >470 msec.
- Use of ≥10 mg of prednisone or equivalent dose of steroids per day within 3 months of administration (inhaled, intranasal, intraocular, topical and intraarticular joint injections of corticosteroids are allowed).Participants with a history of HCV infection who have not completed curative anti HCV treatment and whose HCV load is above the limit of quantification. Concurrent HCV treatment is not allowed in the trial.Live viral vaccine therapies within 4 weeks prior to the first dose of study drug.
- Participants who have received treatment with any herbal or alternative therapies within 7 days prior to the first dose of the study drug.
- Male and female participants of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: dose escalation
MC002 dose escalation
|
MC002 is a recombinant antibody-drug conjugate targeting the oncofetal antigen.A complete treatment cycle is defined as 21 calendar days.
MC002 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To assess the Number of patients with Adverse Events (AE)
Tidsram: From enrollmenFrom enrollment until 28 days after last study drug t to the safety follow up
|
Any medical event in a participant which may or may not have a causal relationship with this treatment.
|
From enrollmenFrom enrollment until 28 days after last study drug t to the safety follow up
|
|
Determination of MTD or RP2D
Tidsram: From enrollment until 28 days after last study drug
|
Maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of MC002
|
From enrollment until 28 days after last study drug
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Maximum concentration (Cmax)
Tidsram: From enrollment until 28 days after last study drug
|
The concentration of MC002 (conjugated ADC), total mAb, and free payload (Cmax will be derived).
|
From enrollment until 28 days after last study drug
|
|
ADA
Tidsram: From enrollment until 28 after last study drug
|
Incidence, onset time, and titer of ADAs against MC002
|
From enrollment until 28 after last study drug
|
|
The time taken to reach the maximum concentration (Tmax)
Tidsram: From enrollment until 28 days after last study drug
|
The concentration of MC002 (conjugated ADC), total mAb, and free payload (Tmax will be derived).
|
From enrollment until 28 days after last study drug
|
|
Area Under Curve (AUC)
Tidsram: From enrollment until 28 days after last study drug
|
PK endpoint
|
From enrollment until 28 days after last study drug
|
|
Half life (T1/2)
Tidsram: From enrollment until 28 days after last study drug
|
Half life (T1/2)
|
From enrollment until 28 days after last study drug
|
|
Trough concentration (Cmin)
Tidsram: From enrollment until 28 days after last study drug
|
The concentration of MC002 (conjugated ADC), total mAb, and free payload (Cmin will be derived)
|
From enrollment until 28 days after last study drug
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall response rate (ORR)
Tidsram: From enrollment until 28 days after last study drug.
|
the proportion/percentage of participants with best overall response of CR or PR。
|
From enrollment until 28 days after last study drug.
|
|
progression-free survival (PFS)
Tidsram: From enrollment until 28 days after last study drug.
|
assessed per RECISTv1.1
|
From enrollment until 28 days after last study drug.
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MC002 FIH Study
- Sponsor (Annat bidrag/finansieringsnummer: Sponsor)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .